Cargando…

Brain Metastases Management in Oncogene-Addicted Non-Small Cell Lung Cancer in the Targeted Therapies Era

The therapeutic landscape in patients with advanced non-small-cell lung cancer harboring oncogenic biomarkers has radically changed with the development of targeted therapies. Although lung cancers are known to frequently metastasize to the brain, oncogene-driven non-small-cell lung cancer patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Carlo, Elisa, Bertoli, Elisa, Del Conte, Alessandro, Stanzione, Brigida, Berto, Eleonora, Revelant, Alberto, Spina, Michele, Bearz, Alessandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9223862/ https://www.ncbi.nlm.nih.gov/pubmed/35742920 http://dx.doi.org/10.3390/ijms23126477

Ejemplares similares

Therapeutical Options in ROS1—Rearranged Advanced Non Small Cell Lung Cancer
por: Stanzione, Brigida, et al.
Publicado: (2023)

Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?
por: Bertoli, Elisa, et al.
Publicado: (2022)

Bone Metastasis and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC): Microenvironment and Possible Clinical Implications
por: Del Conte, Alessandro, et al.
Publicado: (2022)

The Change in Paradigm for NSCLC Patients with EML4–ALK Translocation
por: Bearz, Alessandra, et al.
Publicado: (2022)

Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications
por: Bertoli, Elisa, et al.
Publicado: (2023)

Targeted Therapy and Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Ongoing Trials
por: de Scordilli, Marco, et al.
Publicado: (2022)

NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease
por: Michelotti, Anna, et al.
Publicado: (2022)

Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience
por: De Carlo, Elisa, et al.
Publicado: (2018)

Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer
por: Turkaj, Ana, et al.
Publicado: (2018)

Therapeutic decision based on molecular detection of resistance mechanism in an ALK-rearranged lung cancer patient: a case report
por: De Carlo, Elisa, et al.
Publicado: (2018)

Immune checkpoint inhibitors and response analysis: a tough challenge. A case report
por: Bearz, Alessandra, et al.
Publicado: (2016)

Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment
por: Remon, J., et al.
Publicado: (2018)

Targeting of non-oncogene addiction
por: Igea, Ana, et al.
Publicado: (2015)

Concurrent chemoradiotherapy with tomotherapy in locally advanced non-small cell lung cancer: a phase i, docetaxel dose-escalation study, with hypofractionated radiation regimen
por: Bearz, Alessandra, et al.
Publicado: (2013)

Oncogenic mutation or overexpression of oncogenic KRAS or BRAF is not sufficient to confer oncogene addiction
por: Ito, Reina E., et al.
Publicado: (2021)

Oncogene addiction: resetting the safety switch?
por: Li, Yulin, et al.
Publicado: (2014)

BIM-mediated apoptosis and oncogene addiction
por: Li, Yulin, et al.
Publicado: (2016)

Rhabdomyosarcomas are oncogene addicted to the activation of AVIL
por: Xie, Zhongqiu, et al.
Publicado: (2022)

Immunotherapy in oncogene addicted non-small cell lung cancer
por: McLean, Luke, et al.
Publicado: (2021)

Treating EGFR-Mutated Oncogene-Addicted Advanced Non–Small-Cell Lung Cancer in the Era of Economic Crisis in Greece: Challenges and Opportunities
por: Fountzilas, Elena, et al.
Publicado: (2018)

Drugging the addict: non‐oncogene addiction as a target for cancer therapy
por: Nagel, Remco, et al.
Publicado: (2016)

Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives
por: Ferrara, Miriam Grazia, et al.
Publicado: (2020)

Activity of crizotinib over choroidal metastases in Non-Small-Cell Lung Cancer (NSCLC)-ALK rearranged: a case report
por: Bearz, Alessandra, et al.
Publicado: (2014)

Oncogene addiction to c-MYC in myeloma cells
por: Holien, Toril, et al.
Publicado: (2012)

Oncogenic addiction to high 26S proteasome level
por: Tsvetkov, Peter, et al.
Publicado: (2018)

Oncogene addiction and immune escape: friends or foes?
por: Abdayem, Pamela, et al.
Publicado: (2020)

Targeting Non-Oncogene Addiction for Cancer Therapy
por: Chang, Hae Ryung, et al.
Publicado: (2021)

Oncogene-like addiction to aneuploidy in human cancers
por: Girish, Vishruth, et al.
Publicado: (2023)

Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation
por: Virzì, Anna Rita, et al.
Publicado: (2018)

Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer
por: Listì, Angela, et al.
Publicado: (2019)

Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer
por: Calabrese, Fiorella, et al.
Publicado: (2022)

Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells
por: Amin, Amit Dipak, et al.
Publicado: (2015)

Editorial: New addictions in the era of digitalization
por: Feher, Gergely, et al.
Publicado: (2023)

Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?
por: Schoenmaekers, Janna Josephus Anna Oda, et al.
Publicado: (2020)

Oncogene addiction in gliomas: Implications for molecular targeted therapy
por: Yan, Wei, et al.
Publicado: (2011)

Targeting Non-Oncogene Addiction: Focus on Thyroid Cancer
por: Anania, Maria Chiara, et al.
Publicado: (2020)

Colon Rectal Liver Metastases: The Role of the Liver Transplantation in the Era of the Transplant Oncology and Precision Medicine
por: Finotti, Michele, et al.
Publicado: (2021)

Role of Radiosurgery and Stereotactic Ablative Radiotherapy for Oligometastatic Non-Oncogene Addicted NSCLC
por: Badellino, Serena, et al.
Publicado: (2022)

Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer
por: Russo, Francesca, et al.
Publicado: (2008)

Targeting STAT3 and oxidative phosphorylation in oncogene-addicted tumors
por: Lee, Matilda, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_sv3fhgqgf547bskuiakpqotcm8